Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIUPRES-250 vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diupres-250 is a combination of hydrochlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal convoluted tubule of the kidney, increasing excretion of sodium and water. Reserpine depletes catecholamines and serotonin from presynaptic nerve terminals by irreversibly binding to vesicular monoamine transporter (VMAT), leading to reduced sympathetic outflow and hypotension.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Hypertension (adjunctive therapy),Edema associated with congestive heart failure, cirrhosis, or renal disease (hydrochlorothiazide component)
Hypertension
1 tablet (containing 250 mg chlorothiazide and 0.125 mg reserpine) orally once daily, increased to 2 tablets daily if needed.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Hydroflumethiazide: 6-18 hours (prolonged in renal impairment). Reserpine: 50-100 hours (biphasic; terminal phase).
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Hydrochlorothiazide is not metabolized; excreted unchanged by the kidneys. Reserpine undergoes extensive hepatic metabolism via CYP3A4 oxidation.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal: approximately 50% of hydroflumethiazide is excreted unchanged in urine; reserpine is extensively metabolized with <1% excreted unchanged. Fecal: minimal.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Hydroflumethiazide: 75-80% bound to plasma proteins. Reserpine: approximately 95% bound (primarily to albumin).
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
Hydroflumethiazide: 3-8 L/kg (extensive distribution). Reserpine: 9-12 L/kg (highly lipid-soluble, crosses blood-brain barrier).
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral: hydroflumethiazide ~70% (variability); reserpine ~40% (first-pass metabolism).
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
Contraindicated if GFR <30 m L/min. For GFR 30-60 m L/min: use 1 tablet every other day; avoid if GFR <30 m L/min.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or increase dosing interval. Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Not recommended for pediatric use due to reserpine component; safety and efficacy not established.
Not established; avoid use in children.
Initiate at 1 tablet every other day; monitor for electrolyte disturbances, orthostatic hypotension, and central nervous system effects.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
No FDA black box warning identified. Reserpine use may be associated with increased risk of breast cancer (historical concern, not confirmed), but no official boxed warning.
None
Electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia),Hyperuricemia and gout,Increased blood urea nitrogen (BUN) and creatinine,Photosensitivity with thiazides,Mental depression with reserpine (history of depression, suicidal ideation),Bradycardia, hypotension, and sedation with reserpine,Exacerbation of peptic ulcer disease (reserpine increases gastric acid secretion),Possible withdrawal syndromes (severe hypertension, tachycardia) upon abrupt discontinuation
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Hypersensitivity to hydrochlorothiazide, reserpine, or sulfonamide-derived drugs,Anuria or severe renal impairment,Active peptic ulcer disease or ulcerative colitis,History of major depression or electroconvulsive therapy,Concurrent use with MAO inhibitors (MAOIs) or within 14 days of discontinuation,Pheochromocytoma (reserpine may cause paradoxical hypertension),Electroconvulsive therapy (relative contraindication due to risk of prolonged seizure or apnea)
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Avoid high-sodium foods to enhance antihypertensive effect. Alcohol may increase orthostatic hypotension. Grapefruit juice may alter reserpine metabolism (caution). Avoid tyramine-rich foods (e.g., aged cheeses, cured meats) if also taking MAOIs, but not typically required with reserpine alone. Maintain adequate potassium intake (bananas, oranges) due to hydrochlorothiazide-induced potassium loss.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
First trimester: Use cautiously due to potential fetal bradycardia from the reserpine component; second and third trimesters: Risk of fetal hypotension, bradycardia, and hypothermia; reserpine crosses placenta and may cause neonatal respiratory depression and nasal congestion.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Excreted in breast milk; M/P ratio not established; reserpine may cause infant drowsiness, bradycardia, and GI upset; hydrochlorothiazide may decrease milk supply; generally avoid breastfeeding or use with caution.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
Increased plasma volume and renal clearance in pregnancy may require dose adjustment for hydrochlorothiazide; reserpine pharmacokinetics not well studied; use lowest effective dose; gradual dose reduction recommended near term to avoid neonatal effects.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
DIUPRES-250 (hydrochlorothiazide 25 mg / reserpine 0.125 mg) is a fixed-dose combination antihypertensive. Reserpine depletes catecholamines, causing orthostatic hypotension and nasal congestion. Hydrochlorothiazide may cause hypokalemia, hyperglycemia, and photosensitivity. Avoid in patients with history of depression (reserpine). Monitor serum potassium, glucose, and uric acid. Onset of full effect may take weeks due to reserpine.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take this medication exactly as prescribed, at the same time each day.,Stand up slowly to avoid dizziness or fainting.,Expect nasal congestion which may improve over time.,Use sunscreen and protective clothing to avoid sunburn.,Do not stop abruptly without consulting your doctor (risk of severe hypertension).,Report any mood changes, breast tenderness, or abdominal pain to your doctor.,Avoid driving or operating machinery until you know how this medicine affects you.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIUPRES-250 vs ALDORIL 25, answered by our medical review team.
DIUPRES-250 is a Antihypertensive Combination that works by Diupres-250 is a combination of hydrochlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal convoluted tubule of the kidney, increasing excretion of sodium and water. Reserpine depletes catecholamines and serotonin from presynaptic nerve terminals by irreversibly binding to vesicular monoamine transporter (VMAT), leading to reduced sympathetic outflow and hypotension.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIUPRES-250 and ALDORIL 25 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIUPRES-250 is: 1 tablet (containing 250 mg chlorothiazide and 0.125 mg reserpine) orally once daily, increased to 2 tablets daily if needed.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIUPRES-250 and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIUPRES-250 is classified as Category C. First trimester: Use cautiously due to potential fetal bradycardia from the reserpine component; second and third trimesters: Risk of fetal hypotension, bradycardia, and hypothermi. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.